131 related articles for article (PubMed ID: 12604234)
1. 17-beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold.
Brown WM; Metzger LE; Barlow JP; Hunsaker LA; Deck LM; Royer RE; Vander Jagt DL
Chem Biol Interact; 2003 Feb; 143-144():481-91. PubMed ID: 12604234
[TBL] [Abstract][Full Text] [Related]
2. Expression and purification of active human 17β-Hydroxysteroid dehydrogenase type 1 from Escherichia coli.
Bekić SS; Plavša JJ; Pavšič M; Lenarčič B; Petri ET; Ćelić AS
Acta Chim Slov; 2024 Apr; 71(2):256-263. PubMed ID: 38919102
[TBL] [Abstract][Full Text] [Related]
3. Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17beta-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells.
Sherbet DP; Guryev OL; Papari-Zareei M; Mizrachi D; Rambally S; Akbar S; Auchus RJ
Endocrinology; 2009 Sep; 150(9):4154-62. PubMed ID: 19556422
[TBL] [Abstract][Full Text] [Related]
4. The impact of testosterone, tibolone and black cohosh on purified mammary and placental 17β-hydroxysteroid dehydrogenase type 1.
Stute P; Kalkhake K; Kiesel L; Götte M
J Enzyme Inhib Med Chem; 2015 Jun; 30(3):448-57. PubMed ID: 25109879
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.
Kruchten P; Werth R; Bey E; Oster A; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
J Steroid Biochem Mol Biol; 2009 Apr; 114(3-5):200-6. PubMed ID: 19429452
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Brozic P; Lanisnik Risner T; Gobec S
Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
[TBL] [Abstract][Full Text] [Related]
9. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors.
Breton R; Housset D; Mazza C; Fontecilla-Camps JC
Structure; 1996 Aug; 4(8):905-15. PubMed ID: 8805577
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor.
Verma MK; Miki Y; Abe K; Suzuki T; Niikawa H; Suzuki S; Kondo T; Sasano H
J Transl Med; 2013 Jul; 11():167. PubMed ID: 23837683
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Messinger J; Hirvelä L; Husen B; Kangas L; Koskimies P; Pentikäinen O; Saarenketo P; Thole H
Mol Cell Endocrinol; 2006 Mar; 248(1-2):192-8. PubMed ID: 16413669
[TBL] [Abstract][Full Text] [Related]
13. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
[TBL] [Abstract][Full Text] [Related]
14. Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase.
Mazza C; Breton R; Housset D; Fontecilla-Camps JC
J Biol Chem; 1998 Apr; 273(14):8145-52. PubMed ID: 9525918
[TBL] [Abstract][Full Text] [Related]
15. Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors.
Tremblay MR; Lin SX; Poirier D
Steroids; 2001 Nov; 66(11):821-31. PubMed ID: 11576622
[TBL] [Abstract][Full Text] [Related]
16. Computational investigation of the binding mode of bis(hydroxylphenyl)arenes in 17β-HSD1: molecular dynamics simulations, MM-PBSA free energy calculations, and molecular electrostatic potential maps.
Negri M; Recanatini M; Hartmann RW
J Comput Aided Mol Des; 2011 Sep; 25(9):795-811. PubMed ID: 21822722
[TBL] [Abstract][Full Text] [Related]
17. Chemical synthesis of C3-oxiranyl/oxiranylmethyl-estrane derivatives targeted by molecular modeling and tested as potential inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Lespérance M; Barbeau X; Roy J; Maltais R; Lagüe P; Poirier D
Steroids; 2018 Dec; 140():104-113. PubMed ID: 30273695
[TBL] [Abstract][Full Text] [Related]
18. C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships.
Sam KM; Boivin RP; Tremblay MR; Auger S; Poirier D
Drug Des Discov; 1998 May; 15(3):157-80. PubMed ID: 9689499
[TBL] [Abstract][Full Text] [Related]
19. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
20. Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution.
Ghosh D; Pletnev VZ; Zhu DW; Wawrzak Z; Duax WL; Pangborn W; Labrie F; Lin SX
Structure; 1995 May; 3(5):503-13. PubMed ID: 7663947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
